ArticleCancer medicine2020

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis.

Peng-Fei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.